Larimar Therapeutics, Inc. — fact timeline

Larimar Therapeutics, Inc. shareholders approved Approval of an adjournment of the Annual Meeting to the extent there were insufficient votes to approve Proposal 5 at the 2026-05-19 meeting.

“Proposal 6 - Approval of an adjournment of the Annual Meeting. The stockholders approved an adjournment of the Annual Meeting to the extent there were insufficient votes to approve Proposal 5, but such an adjournment was not necessary in light of the approval of Proposal 5 at the Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 89,887,684 958,761 39,485 0”

Larimar Therapeutics, Inc. shareholders approved Approval of an amendment to the Ninth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of Common Stock from 115,000,000 to 215,000,000 at the 2026-05-19 meeting.

“Proposal 5 - Approval of an amendment to the Ninth Amended and Restated Certificate of Incorporation, as amended. The stockholders approved an amendment to the Company’s Ninth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s Common Stock from 115,000,000 to 215,000,000, as follows: Votes For Votes Against Abstentions Broker Non-Votes 89,732,486 1,046,555 106,889 0”

Larimar Therapeutics, Inc. shareholders approved Ratification of Independent Registered Public Accountant at the 2026-05-19 meeting.

“Proposal 4 - Ratification of Independent Registered Public Accountant. The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified, as follows: Votes For Votes Against Abstentions Broker Non-Votes 90,784,651 72,972 28,307 0”

Larimar Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company's named executive officers at the 2026-05-19 meeting.

“Proposal 3 – Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company’s named executive officers. The stockholders indicated, on an advisory basis, the preferred frequency of one year for future advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows: Every Year Every Two Years Every Three Years Abstentions Broker Non-Votes 72,645,858 71,449 2,633,106 46,263 15,489,254”

Larimar Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2025 at the 2026-05-19 meeting.

“Proposal 2 - Approval, on an advisory basis, of the compensation of the Company’s named executive officers in 2025. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers in 2025, as follows: Votes For Votes Against Abstentions Broker Non-Votes 73,822,237 1,498,429 76,010 15,489,254”

Larimar Therapeutics, Inc. shareholders approved Election of Class III Directors at the 2026-05-19 meeting.

“Proposal 1 - Election of Class III Directors. Frank Thomas, Carole S. Ben-Maimon, M.D. and Joseph Truitt were elected to the Board of Directors of the Company as Class III directors to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successors, if any, are duly elected and qualified or appointed, or their earlier death, resignation, or removal, as follows: Name Votes For Votes Withheld Broker Non-Votes Frank Thomas 66,827,378 8,569,298 15,489,254 Carole S. Ben-Maimon, M.D. 67,314,208 8,082,468 15,489,254 Joseph Truitt 66,445,617 8,951,059 15,489,254”

Larimar Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income net loss for the first quarter of 2026 of $29.6 million, or $0.31 per share of common stock, EPS $0.31 per share of common stock.

“The Company reported a net loss for the first quarter of 2026 of $29.6 million, or $0.31 per share of common stock, compared to a net loss of $29.3 million, or $0.46 per share of common stock, for the first quarter of 2025.”

Larimar Therapeutics, Inc. reported the fourth quarter of 2025 and for the year ended December 31, 2025 results: net income $62.5 million, or $0.73 per share of common stock.

“On March 19, 2026, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the fourth quarter of 2025 and for the year ended December 31, 2025.”

Larimar Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Guggenheim Securities, LLC valued at 20,000,000 shares at $5.00 per share, option for additional 3,000,000 shares exercised, net proceeds (effective 2026-02-25).

“On February 25, 2026, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 20,000,000 shares (the “ Firm Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”), of the Company at a public offering price of $5.00 per share (the “ Offering ”).”

Larimar Therapeutics, Inc. issued 250,000 shares of Series A convertible preferred stock of preferred stock to Blue Owl Healthcare Opportunities IV Public Investments LP for 2,500,000 shares of common stock.

“On January 21, 2026, Larimar Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with Blue Owl Healthcare Opportunities IV Public Investments LP (the “Stockholder”), pursuant to which the Stockholder exchanged 2,500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for 250,000 shares of Series A convertible preferred stock, a “toothless” preferred stock, par value $0.001 per share (the “Series A Convertible Preferred Stock”) (the “Exchange”).”

Larimar Therapeutics, Inc. issued 250,000 shares of newly designated Series A convertible preferred stock of preferred stock to Blue Owl Healthcare Opportunities IV Public Investments LP.

“On December 16, 2025, Larimar Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with Blue Owl Healthcare Opportunities IV Public Investments LP (the “Stockholder”), pursuant to which the Stockholder exchanged 2,500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for 250,000 shares of newly designated Series A convertible preferred stock, a “toothless” preferred stock, par value $0.001 per share (the “Preferred Stock”) (the “Exchange”).”

Larimar Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $14.7 million, EPS $0.27 per share.

“The Company reported a net loss for the first quarter of 2024 of $14.7 million, or $0.27 per share, compared to a net loss of $6.5 million, or $0.15 per share, for the first quarter of 2023.”

Larimar Therapeutics, Inc. reported the fourth quarter of 2023 and for the year ended December 31, 2023 results: net income $13.0 million, EPS $0.30 per share.

“The Company reported a net loss for the fourth quarter of 2023 of $13.0 million, or $0.30 per share, compared to a net loss of $9.4 million, or $0.21 per share, for the fourth quarter of 2022.”

Larimar Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein valued at approximately $161.8 million (effective 2024-02-14).

“On February 14, 2024, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten public offering (the “ Offering ”) of 17,162,472 shares (the “ Shares ”) of the common stock, par value $0.001 per share (the “ Common Stock ”), of the Company at a public offering price of $8.74 per share, less the underwriting discounts and commissions.”

Larimar Therapeutics, Inc. terminated Sales Agreement with Guggenheim Securities, LLC valued at Aggregate offering price of up to $50,000,000; no shares sold under the agreement (effective 2024-02-13).

“On February 13, 2024, Larimar Therapeutics, Inc. (the “ Company ”) gave notice to terminate the Sales Agreement that the Company entered into with Guggenheim Securities, LLC on November 10, 2022 (the “ Sales Agreement ”). Termination of the Sales Agreement was effective February 13, 2024.”

Larimar Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $9.1 million, or $0.21 per share, EPS ($0.21) per share.

“Larimar Therapeutics, Inc. (the " Company ") announced its financial results and operational highlights for the third quarter ended September 30, 2023.”

Jeffrey W. Sherman was appointed as Class I Director at Larimar Therapeutics, Inc..

“On October 3, 2023 (the “ Appointment Date ”), the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”) increased the size of the Board from five to six members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Jeffrey W. Sherman, MD, FACP to serve as a Class I director, with an initial term expiring at the Company’s 2024 Annual Meeting of Stockholders, and a member of the Nominating and Corporate Governance Committee.”

Larimar Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $8.4 million, or $0.19 per share, EPS $0.19 per share.

“The Company reported a net loss for the second quarter of 2023 of $8.4 million, or $0.19 per share, compared to a net loss of $8.7 million, or $0.47 per share, for the second quarter of 2022.”

Larimar Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.

“On May 15, 2023, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the first quarter ended March 31, 2023.”

Larimar Therapeutics, Inc. shareholders approved Ratification of Independent Registered Public Accountant at the 2023-05-09 meeting.

“Proposal 3 – Ratification of Independent Registered Public Accountant. The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified, as follows: Votes For Votes Against Abstentions Broker Non-Votes 40,769,530 6,201 2,448 0”

Larimar Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2022 at the 2023-05-09 meeting.

“Proposal 2 – Approval, on an advisory basis, of the compensation of the Company’s named executive officers in 2022. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers in 2022, as follows: Votes For Votes Against Abstentions Broker Non-Votes 35,507,612 337,895 55,741 4,876,931”

Larimar Therapeutics, Inc. shareholders approved Election of Class III Directors at the 2023-05-09 meeting.

“Proposal 1 – Election of Class III Directors. Frank Thomas, Carole S. Ben-Maimon, M.D. and Joseph Truitt were elected to the Board of Directors of the Company as Class III directors to serve until the Company’s 2026 Annual Meeting of Stockholders and until their successors, if any, are duly elected and qualified or appointed, or their earlier death, resignation, or removal, as follows: Name Votes For Votes Withheld Broker Non-Votes Frank Thomas 27,741,876 8,159,372 4,876,931 Carole S. Ben-Maimon, M.D. 27,757,513 8,143,735 4,876,931 Joseph Truitt 27,378,190 8,523,058 4,876,931”

Peter Barrett resigned as Director at Larimar Therapeutics, Inc..

“On April 3, 2023, Peter Barrett, Ph.D., a member of the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”), tendered his resignation from the Board to be effective as of May 9, 2023, the date of the Company’s 2023 Annual Meeting of Stockholders.”

Larimar Therapeutics, Inc. reported the year ended December 31, 2022 results: net income net loss of $35.4 million, EPS $1.37 per share.

“For the full year 2022, the Company reported a net loss of $35.4 million, or $1.37 per share, compared to a net loss of $50.6 million, or $2.95 per share for the same period in 2021.”

Larimar Therapeutics, Inc. reported fourth quarter of 2022 results: net income net loss of $9.4 million, EPS $0.21 per share.

“The Company reported a net loss for the fourth quarter of 2022 of $9.4 million, or $0.21 per share, compared to a net loss of $9.1 million, or $0.50 per share, for the fourth quarter of 2021.”

Larimar Therapeutics, Inc. reported the nine months ended September 30, 2022 results: net income a net loss for the nine months ended September 30, 2022 of $25.9 million, or $1.32 per share, EPS $1.32 per share.

“The Company reported a net loss for the nine months ended September 30, 2022 of $25.9 million, or $1.32 per share, compared to a net loss of $41.5 million, or $2.48 per share, for the nine months ended September 30, 2021.”

Larimar Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income a net loss for the third quarter of 2022 of $8.3 million, or $0.37 per share, EPS $0.37 per share.

“The Company reported a net loss for the third quarter of 2022 of $8.3 million, or $0.37 per share, compared to a net loss of $16.8 million, or $0.92 per share, for the third quarter of 2021.”

Thomas O. Daniel departed as Class II director at Larimar Therapeutics, Inc..

“On April 6, 2022, Thomas O. Daniel, Ph.D., a member of the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”), notified the Company that he will not stand for re-election as a Class II director at the Company’s 2022 Annual Meeting of Stockholders (the “ Annual Meeting ”), and therefore, will no longer serve as a director of the Company or on any committee of the Board, effective as of the conclusion of the Annual Meeting.”